Table 1.
IC50 of Doxorubicin (DOX) or Paclitaxel (PTX) on the Viability of RL95-2 and AN3 Cell Lines with Forced or Depleted Expression of ARTN.
| Cell Line | IC50 | ||
| DOX (µM) | PTX (nM) | ||
| RL95-2 | Wild-type | 6.19 ± 0.17 | 119.21 ± 7.24 |
| Vector | 6.17 ± 0.26 | 129.00 ± 8.34 | |
| ARTN | 12.33 ± 0.60 | 199.90 ± 4.80 | |
| sivector | 6.16 ± 0.26 | 125.20 ± 9.03 | |
| siARTN | 3.27 ± 0.42 | 72.34 ± 6.23 | |
| AN-3 | Wild-type | 6.23 ± 0.11 | 96.84 ± 8.27 |
| Vector | 6.24 ± 0.22 | 82.12 ± 6.90 | |
| ARTN | 12.56 ± 0.36 | 279.19 ± 15.41 | |
| sivector | 6.17 ± 0.29 | 100.10 ± 6.05 | |
| siARTN | 3.04 ± 0.47 | 50.05 ± 2.99 | |
Cell viability was measured using the MIT assay after a 72-hour drug exposure period with DOX or PTX followed by a 24-hour drug-free period as described in Materials and Methods. IC50 values are presented as mean ± SD of three independent experiments.